Codiak BioSciences is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics. Co. used its engineering and manufacturing platform (engEx Platform) to generate a pipeline of exosomes for treating a range of diseases, including oncology, neuro-oncology, neuromuscular disease, infectious and rare diseases. Co. initiated clinical trials of its key engEx product candidates, exoSTING and exoIL-12, which are being developed to address solid tumors. Co.'s third program, exoASO-STAT6, is an exosome engineered using its engEx Platform to overexpress prostaglandin F2 receptor negative regulator to target uptake in M2-polarized tumor-associated-macrophages. The CDAK stock yearly return is shown above.
The yearly return on the CDAK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CDAK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|